BR112015027400A2 - ANTIBODIES CAPABLE OF SPECIFICALLY BINDING TO HER2 - Google Patents

ANTIBODIES CAPABLE OF SPECIFICALLY BINDING TO HER2

Info

Publication number
BR112015027400A2
BR112015027400A2 BR112015027400A BR112015027400A BR112015027400A2 BR 112015027400 A2 BR112015027400 A2 BR 112015027400A2 BR 112015027400 A BR112015027400 A BR 112015027400A BR 112015027400 A BR112015027400 A BR 112015027400A BR 112015027400 A2 BR112015027400 A2 BR 112015027400A2
Authority
BR
Brazil
Prior art keywords
her2
antibodies
present
trastuzumab
epitope
Prior art date
Application number
BR112015027400A
Other languages
Portuguese (pt)
Other versions
BR112015027400B1 (en
Inventor
Kim Kyu-Tae
LEE Sook-Yeon
KO Bong-Kook
Lee Jong-Seo
Lee Young-Ha
Hwang In-Sik
Original Assignee
Abclon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abclon Inc filed Critical Abclon Inc
Publication of BR112015027400A2 publication Critical patent/BR112015027400A2/en
Publication of BR112015027400B1 publication Critical patent/BR112015027400B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

ANTICORPOS CAPAZES DE SE LIGAR ESPECIFICAMENTE AO HER2. A presente invenção se refere a anticorpos ao HER2 (Receptor 2 de Fator de Crescimento Epidérmico Humano) para prevenir ou tratar cânceres. Os anticorpos da presente invenção se ligam especificamente ao HER2 superexpresso em células cancerosas (em particular, células de câncer de mama e câncer de estômago), especificamente a um epítopo sobre HER2 que é diferente do epítopo para o trastuzumabe. As sequências de CDR dos presentes anticorpos exibem baixa similaridade com sequências de CDR de anticorpos HER2 conhecidos publicamente, significando que as sequências de CDR são únicas. Os anticorpos da presente invenção, em combinação com o trastuzumabe, matam as células cancerosas com citotoxicidade significativamente aprimorada e, portanto, são muito eficazes em terapia de câncer (particularmente, câncer de mama e câncer de estômago). Sem pretender ficar limitado pela teoria, as eficácias aprimoradas da terapia combinada significam que os anticorpos da presente invenção se ligam a um epítopo sobre HER2 que é diferente do epítopo para o trastuzumabe e inibem o HER2 de um modo cooperativo com o trastuzumabe.ANTIBODIES CAPABLE OF SPECIFICALLY BINDING TO HER2. The present invention relates to antibodies to HER2 (Human Epidermal Growth Factor Receptor 2) to prevent or treat cancers. Antibodies of the present invention specifically bind to HER2 overexpressed in cancer cells (in particular, breast cancer and stomach cancer cells), specifically to an epitope on HER2 that is different from the epitope for trastuzumab. The CDR sequences of the present antibodies exhibit low similarity with CDR sequences of publicly known HER2 antibodies, meaning that the CDR sequences are unique. Antibodies of the present invention, in combination with trastuzumab, kill cancer cells with significantly enhanced cytotoxicity and are therefore very effective in cancer therapy (particularly breast cancer and stomach cancer). Without wishing to be bound by theory, the improved efficiencies of the combination therapy means that the antibodies of the present invention bind to an epitope on HER2 that is different from the epitope for trastuzumab and inhibit HER2 in a cooperative manner with trastuzumab.

BR112015027400-5A 2013-05-16 2014-05-14 ANTIBODY CAPABLE OF SPECIFICALLY BINDING TO HER2 OR ANTIGEN-BINDING FRAGMENT THEREOF, PHARMACEUTICAL COMPOSITIONS AND KITS COMPRISING THE SAME, AS WELL AS USE THEREOF TO PREVENT OR TREAT CANCER AND/OR INDUCE APOPTOSIS BR112015027400B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2013-0055912 2013-05-16
KR20130055912 2013-05-16
PCT/KR2014/004317 WO2014185704A1 (en) 2013-05-16 2014-05-14 Antibody specifically binding to her2

Publications (2)

Publication Number Publication Date
BR112015027400A2 true BR112015027400A2 (en) 2017-08-29
BR112015027400B1 BR112015027400B1 (en) 2023-04-25

Family

ID=51898619

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015027400-5A BR112015027400B1 (en) 2013-05-16 2014-05-14 ANTIBODY CAPABLE OF SPECIFICALLY BINDING TO HER2 OR ANTIGEN-BINDING FRAGMENT THEREOF, PHARMACEUTICAL COMPOSITIONS AND KITS COMPRISING THE SAME, AS WELL AS USE THEREOF TO PREVENT OR TREAT CANCER AND/OR INDUCE APOPTOSIS

Country Status (13)

Country Link
US (1) US10174116B2 (en)
EP (1) EP2998319B1 (en)
JP (2) JP6234548B2 (en)
KR (1) KR101453462B1 (en)
CN (1) CN105164160B (en)
AU (1) AU2014266118B2 (en)
BR (1) BR112015027400B1 (en)
CA (1) CA2910407C (en)
ES (1) ES2710707T3 (en)
HK (1) HK1217500A1 (en)
MX (1) MX368228B (en)
RU (1) RU2628094C2 (en)
WO (1) WO2014185704A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI560213B (en) * 2010-02-10 2016-12-01 Ube Industries Polyimide, manufacturing process thereof, and laminate
TWI695011B (en) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 Monoclonal antibodies against her2 epitope and methods of use thereof
KR101796277B1 (en) * 2016-04-12 2017-11-13 앱클론(주) Antibodies Binding Specifically to HER2 with Improved Stability
EP3241847A1 (en) * 2016-05-06 2017-11-08 MAB Discovery GmbH Her-2 binding antibodies
CN109476744B (en) * 2016-05-12 2023-04-11 新加坡科技研究局 anti-ERBB-2 antibodies and uses thereof
EP3565845A4 (en) 2017-01-06 2020-10-07 Biosion, Inc. Erbb2 antibodies and uses therefore
AU2018224094A1 (en) * 2017-02-24 2019-09-19 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
WO2019098682A1 (en) * 2017-11-14 2019-05-23 앱클론(주) Anti-her2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CN110790840A (en) * 2018-08-01 2020-02-14 三生国健药业（上海）股份有限公司 Antibodies that bind to human HER2, methods of making and uses thereof
KR20200098831A (en) 2019-02-13 2020-08-21 건국대학교 글로컬산학협력단 Novel site-specific antibody fragment platform
EP3962525A1 (en) * 2019-05-02 2022-03-09 MAB Discovery GmbH Combination of her2 antibodies
CN117224689B (en) * 2023-11-16 2024-02-23 上海复宏汉霖生物技术股份有限公司 Use of a combination of an anti-HER 2 antibody and a chemotherapeutic agent for the treatment of gastric cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
DE3785186T2 (en) 1986-09-02 1993-07-15 Enzon Lab Inc BINDING MOLECULE WITH SINGLE POLYPEPTIDE CHAIN.
EP0349578B2 (en) 1987-03-02 1998-10-28 Enzon Labs Inc. Organism carrying a Single Chain Antibody Domain at its surface.
DE3884529T2 (en) 1987-03-20 1994-04-28 Creative Biomolecules Inc LEADER SHARES FOR THE PRODUCTION OF RECOMBINANT PROTEINS.
EP0621340A1 (en) 1987-03-20 1994-10-26 Creative Biomolecules, Inc. Product and process for the production and purification of recombinant polypeptides
DE3856559T2 (en) 1987-05-21 2004-04-29 Micromet Ag Multifunctional proteins with predetermined objectives
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1994000136A1 (en) 1992-06-30 1994-01-06 Oncologix, Inc. A COMBINATION OF ANTI-erbB-2 MONOCLONAL ANTIBODIES AND METHOD OF USING
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
EP1695986B1 (en) * 1996-10-18 2016-12-14 Genentech, Inc. Anti-erb B2 antibodies
US7306801B2 (en) * 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
WO2005044302A1 (en) 2003-11-06 2005-05-19 Pfizer Products Inc. Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer
EP2431050A1 (en) 2004-05-20 2012-03-21 ZymoGenetics, L.L.C. Methods of treating cancer using IL-21 and monoclonal antibody therapy
KR20110050567A (en) * 2004-07-22 2011-05-13 제넨테크, 인크. Her2 antibody composition
US7329737B2 (en) 2004-08-03 2008-02-12 Dyax Corp. Antibodies that bind hK-1
HUE038454T2 (en) * 2006-08-04 2018-10-29 Medimmune Ltd Human antibodies to erbb 2
WO2008031531A1 (en) 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
ES2407957T3 (en) 2007-03-09 2013-06-17 Geron Corporation Treatment of carcinomas with a combination of inhibitors of the EGF pathway and telomerase
EP2448599A1 (en) 2009-06-30 2012-05-09 Philogen S.p.A. Immunocytokines in combination with anti-erbb antibodies for the treatment of cancer
CN102167742B (en) * 2010-02-25 2014-05-14 上海百迈博制药有限公司 Human monoclonal antibody against HER2, preparation method and purpose thereof
WO2012143523A1 (en) * 2011-04-20 2012-10-26 Genmab A/S Bispecifc antibodies against her2

Also Published As

Publication number Publication date
RU2015146664A (en) 2017-06-21
US10174116B2 (en) 2019-01-08
CN105164160B (en) 2018-11-30
MX368228B (en) 2019-09-24
AU2014266118A1 (en) 2015-11-12
WO2014185704A1 (en) 2014-11-20
ES2710707T3 (en) 2019-04-26
AU2014266118B2 (en) 2017-03-30
JP2016518368A (en) 2016-06-23
JP6487968B2 (en) 2019-03-20
RU2628094C2 (en) 2017-08-14
BR112015027400B1 (en) 2023-04-25
JP6234548B2 (en) 2017-11-22
KR101453462B1 (en) 2014-10-23
CA2910407A1 (en) 2014-11-20
HK1217500A1 (en) 2017-01-13
EP2998319A4 (en) 2017-01-25
CN105164160A (en) 2015-12-16
EP2998319B1 (en) 2018-11-28
EP2998319A1 (en) 2016-03-23
JP2018008954A (en) 2018-01-18
MX2015015110A (en) 2016-08-11
US20160053011A1 (en) 2016-02-25
CA2910407C (en) 2018-12-11

Similar Documents

Publication Publication Date Title
BR112015027400A2 (en) ANTIBODIES CAPABLE OF SPECIFICALLY BINDING TO HER2
IL279330A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
IL276434A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
MX2015017485A (en) Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases.
HK1219486A1 (en) Therapy involving antibodies against claudin 18.2 for treatment of cancer 18.2
HK1213925A1 (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer 18.2
WO2014113429A3 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
RS58944B1 (en) Pertuzumab, trastuzumab, docetaxel and carboplatin for the treatment of early-stage breast cancer
BR112012030479A2 (en) enhanced cancer therapy based on d1 cyclin-derived tumor-associated antigens
NZ630881A (en) Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ625758A (en) Method for treating breast cancer
RS63738B1 (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
SI2976360T1 (en) Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014079931A8 (en) Cd44v6-derived peptides for treating breast cancers
MY174794A (en) Anticancer composition
WO2013053034A3 (en) Thiazacridines used in anti-cancer therapy

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/05/2014, OBSERVADAS AS CONDICOES LEGAIS